Gerald Chi
scholar.google.com
0000-0002-8371-1689
122 papers found
Refreshing results…
Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy
Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation
D-dimer concentration is associated with increased risk for VTE and greater absolute benefit of extended prophylaxis with betrixaban in acutely III medical patients: insights from the APEX trial
Betrixaban Reduces Not Only the Presence of Thrombus but Also Extent of Thrombus: An APEX Trial Substudy
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy
History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial
P4565 Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy.
P5600 History of venous thromboembolism is associated with higher risk for recurrent venous thromboembolism: insights from the APEX trial.
Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy.
Abstract 19512: Characterization of Access vs. Non-Access Site Bleeding Following PCI in Patients With Atrial Fibrillation.
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy
Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy
P6112 Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial.
P4316 N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy.
Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban)
Abstract 299: Effect of Low-Dose versus Very-Low-Dose Rivaroxaban on Stroke and Major Bleeding Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: A Bivariate Analysis on the Net Clinical Benefit.
Bivariate Analysis of Major Adverse Cardiac Events and Serious Adverse Events in Clinical Trials Comparing Intensive Versus Standard Blood Pressure Control Strategy
Abstract 502: Effect of Intensive Versus Standard Blood Pressure Control on Stroke and Serious Adverse Event: A Bivariate Analysis on the Net Clinical Benefit.
Letter by Chi and Marszalek Regarding Article,“Composite End Points in Clinical Research: A Time for Reappraisal”
Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial
Missing publications? Search for publications with a matching author name.